ChemoID is a functional precision oncology diagnostic for tailoring treatment options.
ChemoID provides a testing environment proven by randomized clinical trials that enables you to evaluate the effectiveness of various treatment choices, complementing genomic testing and practical treatment decisions.
Oncologists face many challenges when determining the best course of treatment for a specific cancer patient. The primary issue is that patients with similar diagnoses do not always respond to the same chemotherapy. Our strategy focuses on discoveries that support the theory that malignant tumors are caused by a small number of tumor-initiating cells with stem cell properties known as cancer stem cells (CSC) that are highly resistant to conventional therapies and are the major underlying cause of tumor recurrence.
We employ innovative and insightful proprietary technologies to predict chemotherapies that selectively eliminate Cancer Stem Cells (CSCs) that cause relapse, allowing us to provide Personalized Cancer Treatment strategies.
We use innovative and insightful proprietary technologies that enable the enrichment of Cancer Stem Cells (CSCs) from biopsies of a patient’s own tumor and that uniquely allows us to develop and deliver Personalized Cancer Treatment strategies. Our goal is to improve the survival rates of cancer patients and to identify novel anticancer drugs against CSCs.
Oncologists face every day many challenges in determining the best course of therapy for an individual cancer patient. The basic problem is that patients with similar diagnoses don’t always respond to the same chemotherapy. Our strategy concentrates on discoveries supporting that malignant tumors are derived from a small number of tumor-initiating cells having stem cell properties called cancer stem cells (CSCs).
ChemoID testing begins with a small tumor sample biopsy, which is sent to our lab to grow cancer cells for testing. The procedure entails growing bulk tumor cells and enriching cancer stem cells derived from individual patient biopsies or fluid samples. These cells are then treated with various standard of care FDA-approved chemotherapeutic agents chosen by the patient’s oncologist to see how many tumor-derived cells and CSCs are killed by each drug or combination. For each drug evaluated, a response curve is generated, and the data is presented graphically to the oncologist as the cytotoxic index.
The ChemoID Assay tests various FDA-approved standard-of-care chemotherapy drugs for efficacy against both CSCs and the bulk of tumor cells. This process determines the most effective combination of chemotherapy drugs to defeat a patient’s cancer, resulting in less toxicity for the patient, lower overall treatment costs, and increased survival rates.
ChemoID test results are reported to the oncologist within 15-20 days, positively impacting patient outcomes. The market demand for a patient-centric approach to cost management and improving patient treatment outcomes is precisely the evolution in Personalized Cancer Treatment that ChemoID is uniquely capable of meeting.
The ChemoID assay can be billed under the PLA code 0435U
Entra in un mondo di opportunità su Hellspin dove ogni giro può trasformarsi in una vincita straordinaria.
